Investigation Report on China Quetiapine Market, 2009-2018

DUBLIN, March 28, 2014 /PRNewswire/ --

Dublin - Research and Markets (http://www.researchandmarkets.com/research/8pl45q/investigation) has announced the addition of the "Investigation Report on China Quetiapine Market, 2009-2018" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


Schizophrenia is a common mental disorder. As a chronic disease, schizophrenia can lead to recurrent or persistent symptoms in most patients' whole life. As Chinese economy and society develops, life and work here has become increasingly stressful. As a result, recurrence rate of schizophrenia has also increased. Statistics shows that the number of schizophrene in China has exceeded 10 million by the end of 2013, and it is still rising year after year.

Quetiapine is originally developed by Astra Zeneca and has curative effect on various schizophrenic symptoms. It was firstly approved to the U.K. market in July 1997 and to the U.S. market on September 26, 1997 by FDA with the trade name ""Seroquel"". Patent of this product expired on March 26, 2012. To prolong its life cycle, long-acting release formulation of quetiapine developed by Astra Zeneca was approved to the U.S. market on May 17, 2007 with the trade name ""Seroquel XR"", which extends its patent protection to November 28, 2017. After that it has come into markets of several countries sequentially, such as Germany and China.

In 2012, global sales revenue of Seroquel and Seroquel XR was USD 2,803 million, of which the former dropped by 70% to USD 1,294 million while the later increased to USD 1,509 million.

The moment the patent of Seroquel expired, it became target of many generic drug manufacturers.

On March 22, 2012, the U.K. High Court ruled that the patent of Seroquel XR prescription was invalid. However, District Court of New Jersey later ruled that patent of Seroquel XR was valid. Consequently, the production of Seroquel generic drug by Anchen, Osmotica, Torrent and Mylan Pharmaceutical Company has violated the patent of Seroquel XR prescription, which expires in 2017.

On March 27, 2012, Teva Pharmaceutical Industries Limited launched generic drugs of Seroquel and Seroquel XL in the U.K. on the same day, Dr. Reddy's Lab from India launched Seroquel generic drug in the U.S. Astra Zeneca permitted Intelli to sell generic drug of Seroquel XL from November 2016.

Quetiapine produced by Astra Zeneca was approved to China in 2000 with the trade name ""Seroquel"". In the same year, Hunan Dongting Pharmaceutical Co., Ltd. became the first approved manufacturer to produce quetiapine raw material and troche with the brand name ""Qi Wei"". In 2003, Suzhou Pharmaceutical Group Co., Ltd. was also approved to produce quetiapine raw material and troche with the brand name ""Shu Si"". Moreover, Chongqing Fuan Pharmaceutical Co., Ltd. and Zhejiang Supor Pharmaceuticals Co., Ltd. received raw material approvals respectively in 2011 and 2012.


Key Topics Covered:

1 Relevant Concepts of Quetiapine

2 Market Overview of Quetiapine in China

3 Investigation on Sales Value of Quetiapine in China, 2009-2013

4 Investigation on Market Share of Major Quetiapine Manufacturers in China, 2009-2013

5 Investigation on Market Size of Quetiapine by Dosage Form in China, 2009-2013

6 Reference Price of Quetiapine Produced by Different Enterprises in China Hospital Market, 2014

7 Analysis on Major Quetiapine Manufacturers in China, 2009-2014

8 Prospect of China Quetiapine Market, 2014-2018

For more information visit http://www.researchandmarkets.com/research/8pl45q/investigation

Media Contact: Laura Wood , +353-1-481-1716, [email protected]

SOURCE Research and Markets